{"rows":[{"id":301,"title":"Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress","authors":"Ibi Daisuke, Takaba Rika, Yoshida Keisuke, Kawase Ririna, Kitagawa Hiroko, Matsushita Momoko, Ito Kana, Uno Shoya, Nishimura Fumiya, Kitagaki Shinji, Hiramatsu Masayuki","journal":"Neuropsychopharmacology Reports","publication_date":"2026-09-01","publication_year":2026,"doi":"10.1002/npr2.70152","pubmed_id":"42379141","openalex_id":"https://openalex.org/W7166665532","source_url":"https://doi.org/10.1002/npr2.70152","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,Anxiety,Receptor Pharmacology,Resilience,Animal Study,Treatment-Resistant Depression","study_type":"Animal Study","source_name":"Crossref","publication_status":"published","date_added":"2026-07-01 06:48:03","last_checked":"2026-08-09 08:28:49","bibtex":null,"source_record_id":"PMID:42379141","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.1002/npr2.70152","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"PMID:42379141","source_url":"https://doi.org/10.1002/npr2.70152","doi":"10.1002/npr2.70152","pmid":"42379141","publication_date":"2026-09-01","importer_version":"2.1.3","text_redistributed":false}},{"id":5871,"title":"Brain-wide reconfiguration of burst firing by psilocybin reveals 5-HT2A-dependent circuit dynamics","authors":"Momi, D.; Nahas, Y.; Wyrick, D.; Marks, L. C.; Claar, L. D.; De Filippo, R.; Seyfourian, P.; Pizzagalli, D. A.; Buice, M.; Ott, T.; Koch, C.; Rembado, I.","journal":"bioRxiv","publication_date":"2026-08-22","publication_year":2026,"doi":"10.64898/2026.08.14.744865","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.08.14.744865","substance_tags":"psilocybin","topic_tags":"Brain Imaging,Receptor Pharmacology,Animal Study","study_type":"Animal Study","source_name":"bioRxiv","publication_status":"preprint","date_added":"2026-08-20 01:27:14","last_checked":"2026-08-23 01:21:56","bibtex":null,"source_record_id":"DOI:10.64898/2026.08.14.744865","abstract_available":true,"abstract_source":"bioRxiv","abstract_source_url":"https://doi.org/10.64898/2026.08.14.744865","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"bioRxiv","source_record_id":"DOI:10.64898/2026.08.14.744865","source_url":"https://doi.org/10.64898/2026.08.14.744865","doi":"10.64898/2026.08.14.744865","pmid":"","publication_date":"2026-08-22","importer_version":"2.1.3","text_redistributed":false}},{"id":4169,"title":"Exploring Psychedelics as Novel Therapeutics for Smoking Cessation: Mechanistic Insights from Animal Studies","authors":"Belle Buzzi","journal":"VCU Scholars Compass (Virginia Commonwealth University)","publication_date":"2026-08-21","publication_year":2026,"doi":"10.25772/0t5k-3r51","pubmed_id":null,"openalex_id":"https://openalex.org/W7127870091","source_url":"https://scholarscompass.vcu.edu/etd/8246","substance_tags":"psilocybin","topic_tags":"Depression,Addiction,Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,Animal Study","study_type":"Animal Study","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:37","last_checked":"2026-08-23 01:20:19","bibtex":null,"source_record_id":"DOI:10.25772/0t5k-3r51","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://scholarscompass.vcu.edu/etd/8246","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.25772/0t5k-3r51","source_url":"https://scholarscompass.vcu.edu/etd/8246","doi":"10.25772/0t5k-3r51","pmid":"","publication_date":"2026-08-21","importer_version":"2.1.3","text_redistributed":false}},{"id":5878,"title":"Psilocybin lengthens hippocampal sharp wave ripples","authors":"Bozkir, I. K.; Lashin, R.; Liu, T.; Pal, D.; Diba, K.; Kinsky, N. R.","journal":"bioRxiv","publication_date":"2026-08-20","publication_year":2026,"doi":"10.64898/2026.08.17.745042","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.08.17.745042","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Neuroplasticity,Receptor Pharmacology","study_type":"Other","source_name":"bioRxiv","publication_status":"preprint","date_added":"2026-08-23 01:20:15","last_checked":"2026-08-23 01:21:56","bibtex":null,"source_record_id":"DOI:10.64898/2026.08.17.745042","abstract_available":true,"abstract_source":"bioRxiv","abstract_source_url":"https://doi.org/10.64898/2026.08.17.745042","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"bioRxiv","source_record_id":"DOI:10.64898/2026.08.17.745042","source_url":"https://doi.org/10.64898/2026.08.17.745042","doi":"10.64898/2026.08.17.745042","pmid":"","publication_date":"2026-08-20","importer_version":"2.1.3","text_redistributed":false}},{"id":5877,"title":"The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A Narrative Review","authors":"Clark Rachel N","journal":"Lynchburg Journal of Medical Science","publication_date":"2026-08-20","publication_year":2026,"doi":"10.63932/3067-7106.1087","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.63932/3067-7106.1087","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Addiction,Pharmacology,Receptor Pharmacology,Aging,Clinical Trial,Review Article,Safety","study_type":"Clinical Trial","source_name":"Crossref","publication_status":"published","date_added":"2026-08-22 01:20:15","last_checked":"2026-08-23 01:20:15","bibtex":null,"source_record_id":"DOI:10.63932/3067-7106.1087","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.63932/3067-7106.1087","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"DOI:10.63932/3067-7106.1087","source_url":"https://doi.org/10.63932/3067-7106.1087","doi":"10.63932/3067-7106.1087","pmid":"","publication_date":"2026-08-20","importer_version":"2.1.3","text_redistributed":false}},{"id":3626,"title":"The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults","authors":"Region Skane","journal":"ClinicalTrials.gov","publication_date":"2026-08-14","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07169747","substance_tags":"psilocybin","topic_tags":"Anxiety,Eating Disorders,Neuroplasticity,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Consciousness,Biomarkers,Aging,Personality Change,Emotional Processing,Mystical Experience,Clinical Trial,Randomized Controlled Trial,Review Article,Animal Study,Adolescents,Healthcare Workers,Safety,Adverse Events,Toxicity,Drug Interactions","study_type":"Randomized Controlled Trial","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:28","last_checked":"2026-08-21 01:27:47","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT07169747","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT07169747","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT07169747","source_url":"https://clinicaltrials.gov/study/NCT07169747","doi":"","pmid":"","publication_date":"2026-08-14","importer_version":"2.1.3","text_redistributed":false}},{"id":3525,"title":"Psilocybin Administration With 5-HT1a Blockade","authors":"Johns Hopkins University","journal":"ClinicalTrials.gov","publication_date":"2026-08-14","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07565493","substance_tags":"psilocybin","topic_tags":"Brain Imaging,Receptor Pharmacology,Consciousness,Observational Study,Healthy Volunteers","study_type":"Clinical Trial","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:27","last_checked":"2026-08-21 01:27:46","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT07565493","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT07565493","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT07565493","source_url":"https://clinicaltrials.gov/study/NCT07565493","doi":"","pmid":"","publication_date":"2026-08-14","importer_version":"2.1.3","text_redistributed":false}},{"id":5863,"title":"Ayahuasca and Salvia divinorum as contrasting modes of consciousness reorganization: Implications for psychedelic-assisted psychotherapy","authors":"Brian Ross","journal":"Journal of Psychedelic Studies","publication_date":"2026-08-13","publication_year":2026,"doi":"10.1556/2054.2026.00517","pubmed_id":null,"openalex_id":"https://openalex.org/W7202362192","source_url":"https://doi.org/10.1556/2054.2026.00517","substance_tags":"psilocybin","topic_tags":"Addiction,Pharmacology,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Consciousness,Emotional Processing,Review Article,Animal Study,Toxicity","study_type":"Review Article","source_name":"OpenAlex","publication_status":"published","date_added":"2026-08-15 01:20:13","last_checked":"2026-08-20 01:20:19","bibtex":null,"source_record_id":"DOI:10.1556/2054.2026.00517","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1556/2054.2026.00517","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1556/2054.2026.00517","source_url":"https://doi.org/10.1556/2054.2026.00517","doi":"10.1556/2054.2026.00517","pmid":"","publication_date":"2026-08-13","importer_version":"2.1.3","text_redistributed":false}},{"id":3684,"title":"TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy","authors":"M.D. Anderson Cancer Center","journal":"ClinicalTrials.gov","publication_date":"2026-08-12","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06200155","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Chronic Pain,Neuroplasticity,Brain Imaging,Receptor Pharmacology,Biomarkers,Wellbeing,Mystical Experience,Healthcare Workers,Safety,Inflammation,Immune Function","study_type":"Other","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:28","last_checked":"2026-08-19 01:24:01","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT06200155","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT06200155","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT06200155","source_url":"https://clinicaltrials.gov/study/NCT06200155","doi":"","pmid":"","publication_date":"2026-08-12","importer_version":"2.1.3","text_redistributed":false}},{"id":3674,"title":"TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors","authors":"M.D. Anderson Cancer Center","journal":"ClinicalTrials.gov","publication_date":"2026-08-12","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06801041","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Chronic Pain,Neuroplasticity,Brain Imaging,Receptor Pharmacology,Biomarkers,Wellbeing,Mystical Experience,Healthcare Workers,Safety,Inflammation,Immune Function","study_type":"Other","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:28","last_checked":"2026-08-19 01:24:01","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT06801041","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT06801041","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT06801041","source_url":"https://clinicaltrials.gov/study/NCT06801041","doi":"","pmid":"","publication_date":"2026-08-12","importer_version":"2.1.3","text_redistributed":false}},{"id":5853,"title":"Psychedelics and astrocytes: a hypothesis-driven perspective on neuro-glial integration, network plasticity, and neuroimmune reprogramming.","authors":"Ke X, Du X, Wang X.","journal":"Molecular psychiatry","publication_date":"2026-08-11","publication_year":2026,"doi":"10.1038/s41380-026-03816-9","pubmed_id":"42581074","openalex_id":null,"source_url":"https://doi.org/10.1038/s41380-026-03816-9","substance_tags":"psilocybin","topic_tags":"Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,Drug Interactions,Immune Function","study_type":"Other","source_name":"Europe PMC","publication_status":"published","date_added":"2026-08-13 01:20:05","last_checked":"2026-08-18 01:20:10","bibtex":null,"source_record_id":"PMID:42581074","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1038/s41380-026-03816-9","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42581074","source_url":"https://doi.org/10.1038/s41380-026-03816-9","doi":"10.1038/s41380-026-03816-9","pmid":"42581074","publication_date":"2026-08-11","importer_version":"2.1.3","text_redistributed":false}},{"id":5847,"title":"An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons.","authors":"Kothiwala FM, Murphy RJ, Alshakhouri M, Douglass HM, Evans WJ, Paterson T, Muthukumaraswamy S, Sumner RL.","journal":"Pharmacology","publication_date":"2026-08-10","publication_year":2026,"doi":"10.1159/pha/aejag002","pubmed_id":"42574302","openalex_id":"https://openalex.org/W7202192981","source_url":"https://doi.org/10.1159/pha/aejag002","substance_tags":"psilocybin","topic_tags":"Brain Imaging,Pharmacology,Receptor Pharmacology,Healthy Volunteers,Safety,Adverse Events","study_type":"Other","source_name":"Europe PMC","publication_status":"published","date_added":"2026-08-11 01:20:06","last_checked":"2026-08-17 01:20:29","bibtex":null,"source_record_id":"PMID:42574302","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1159/pha/aejag002","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42574302","source_url":"https://doi.org/10.1159/pha/aejag002","doi":"10.1159/pha/aejag002","pmid":"42574302","publication_date":"2026-08-10","importer_version":"2.1.3","text_redistributed":false}},{"id":3531,"title":"Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury","authors":"James J. Peters Veterans Affairs Medical Center","journal":"ClinicalTrials.gov","publication_date":"2026-08-10","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07251491","substance_tags":"psilocybin","topic_tags":"Depression,Chronic Pain,Mechanism of Action,Receptor Pharmacology,Wellbeing,Veterans,Safety,Adverse Events","study_type":"Other","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:27","last_checked":"2026-08-17 01:21:44","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT07251491","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT07251491","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT07251491","source_url":"https://clinicaltrials.gov/study/NCT07251491","doi":"","pmid":"","publication_date":"2026-08-10","importer_version":"2.1.3","text_redistributed":false}},{"id":3453,"title":"Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study","authors":"University Health Network, Toronto","journal":"ClinicalTrials.gov","publication_date":"2026-08-10","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06506019","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Consciousness,Aging,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Healthy Volunteers,Treatment-Resistant Depression","study_type":"Randomized Controlled Trial","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:27","last_checked":"2026-08-17 01:21:44","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT06506019","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT06506019","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT06506019","source_url":"https://clinicaltrials.gov/study/NCT06506019","doi":"","pmid":"","publication_date":"2026-08-10","importer_version":"2.1.3","text_redistributed":false}},{"id":5782,"title":"Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges.","authors":"Giovenzana M, Nicosia N, Spinosa S, Musazzi L, Mingardi J.","journal":"Pharmacological research","publication_date":"2026-08-06","publication_year":2026,"doi":"10.1016/j.phrs.2026.108366","pubmed_id":"42562081","openalex_id":"https://openalex.org/W7196936402","source_url":"https://doi.org/10.1016/j.phrs.2026.108366","substance_tags":"psilocybin","topic_tags":"Neuroplasticity,Receptor Pharmacology,Emotional Processing,Observational Study,Animal Study,Safety","study_type":"Observational Study","source_name":"Europe PMC","publication_status":"published","date_added":"2026-08-08 01:20:07","last_checked":"2026-08-13 01:20:27","bibtex":null,"source_record_id":"PMID:42562081","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1016/j.phrs.2026.108366","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42562081","source_url":"https://doi.org/10.1016/j.phrs.2026.108366","doi":"10.1016/j.phrs.2026.108366","pmid":"42562081","publication_date":"2026-08-06","importer_version":"2.1.3","text_redistributed":false}},{"id":1369,"title":"A suite of engineered mice for interrogating psychedelic drug actions.","authors":"Chiu YT, Deutch AY, Wang W, Schmitz GP, Huang KL, Kocak DD, Llorach P, Bowyer KR, Liu B, Sciaky N, Hua K, Chen C, Mott SE, Niehaus J, DiBerto JF, English J, Walsh JJ, Scherrer G, Herman MA, Wu Z, Wetsel WC, Roth BL.","journal":"Nature neuroscience","publication_date":"2026-08-06","publication_year":2026,"doi":"10.1038/s41593-026-02375-0","pubmed_id":"42563032","openalex_id":"https://openalex.org/W4387039546","source_url":"https://doi.org/10.1038/s41593-026-02375-0","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,PTSD,Headache / Migraine,Mechanism of Action,Receptor Pharmacology,Animal Study","study_type":"Animal Study","source_name":"Europe PMC","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-13 01:20:27","bibtex":null,"source_record_id":"PMID:42563032","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1038/s41593-026-02375-0","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42563032","source_url":"https://doi.org/10.1038/s41593-026-02375-0","doi":"10.1038/s41593-026-02375-0","pmid":"42563032","publication_date":"2026-08-06","importer_version":"2.1.3","text_redistributed":false}},{"id":5780,"title":"Mapping excitatory synaptic plasticity evoked by single-dose psilocybin in mice","authors":"Li, Z.; Weber, C.; Sellitti, F.; Simmler, L. D.","journal":"bioRxiv","publication_date":"2026-08-05","publication_year":2026,"doi":"10.64898/2026.07.31.741703","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.07.31.741703","substance_tags":"psilocybin,psilocin","topic_tags":"Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Animal Study,Transcriptomics","study_type":"Animal Study","source_name":"bioRxiv","publication_status":"preprint","date_added":"2026-08-07 01:20:13","last_checked":"2026-08-12 01:26:12","bibtex":null,"source_record_id":"DOI:10.64898/2026.07.31.741703","abstract_available":true,"abstract_source":"bioRxiv","abstract_source_url":"https://doi.org/10.64898/2026.07.31.741703","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"bioRxiv","source_record_id":"DOI:10.64898/2026.07.31.741703","source_url":"https://doi.org/10.64898/2026.07.31.741703","doi":"10.64898/2026.07.31.741703","pmid":"","publication_date":"2026-08-05","importer_version":"2.1.3","text_redistributed":false}},{"id":5775,"title":"Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.","authors":"Ippolito A, Tiranti A, Hurley S, Gilmour G, Churchill G, Sharp T","journal":"ACS chemical neuroscience","publication_date":"2026-08-05","publication_year":2026,"doi":"10.1021/acschemneuro.6c00138","pubmed_id":"42554671","openalex_id":"https://openalex.org/W7172419785","source_url":"https://pubmed.ncbi.nlm.nih.gov/42554671/","substance_tags":"psilocin","topic_tags":"Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Biomarkers,Animal Study","study_type":"Animal Study","source_name":"PubMed","publication_status":"published","date_added":"2026-08-06 01:20:05","last_checked":"2026-08-12 01:20:06","bibtex":null,"source_record_id":"PMID:42554671","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/42554671/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:42554671","source_url":"https://pubmed.ncbi.nlm.nih.gov/42554671/","doi":"10.1021/acschemneuro.6c00138","pmid":"42554671","publication_date":"2026-08-05","importer_version":"2.1.3","text_redistributed":false}},{"id":3437,"title":"Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer","authors":"Yvan Beaussant, MD, MSci","journal":"ClinicalTrials.gov","publication_date":"2026-08-05","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06001749","substance_tags":"psilocybin","topic_tags":"Addiction,End-of-Life Distress,Chronic Pain,Receptor Pharmacology,Clinical Trial,Safety","study_type":"Clinical Trial","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:27","last_checked":"2026-08-12 01:27:30","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT06001749","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT06001749","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT06001749","source_url":"https://clinicaltrials.gov/study/NCT06001749","doi":"","pmid":"","publication_date":"2026-08-05","importer_version":"2.1.3","text_redistributed":false}},{"id":5776,"title":"Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.","authors":"Kuypers KPC, Mason NL, Carlier A, Totomanova I, Haijen-Bongers ECHM.","journal":"Molecular psychiatry","publication_date":"2026-08-04","publication_year":2026,"doi":"10.1038/s41380-026-03801-2","pubmed_id":"42552418","openalex_id":"https://openalex.org/W7172382485","source_url":"https://doi.org/10.1038/s41380-026-03801-2","substance_tags":"psilocin","topic_tags":"Depression,Anxiety,Brain Imaging,Pharmacology,Mechanism of Action,Receptor Pharmacology,Aging,Longevity,Review Article,Animal Study,Safety","study_type":"Review Article","source_name":"Europe PMC","publication_status":"published","date_added":"2026-08-06 01:20:05","last_checked":"2026-08-11 01:20:23","bibtex":null,"source_record_id":"PMID:42552418","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1038/s41380-026-03801-2","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42552418","source_url":"https://doi.org/10.1038/s41380-026-03801-2","doi":"10.1038/s41380-026-03801-2","pmid":"42552418","publication_date":"2026-08-04","importer_version":"2.1.3","text_redistributed":false}}],"total":1284,"page":1,"per_page":20,"pages":65,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":"Receptor Pharmacology","study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":null,"from":null,"to":null,"added_from":null,"added_to":null,"sort":"newest","page":1,"per_page":"20"}}